Cetera Advisors LLC grew its stake in Aurora Cannabis Inc (NYSE:ACB) by 5.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,092 shares of the company’s stock after acquiring an additional 3,899 shares during the period. Cetera Advisors LLC’s holdings in Aurora Cannabis were worth $336,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mackey Komara & Dankovich LLC bought a new position in shares of Aurora Cannabis in the 2nd quarter valued at about $27,000. Sandy Spring Bank grew its holdings in shares of Aurora Cannabis by 210.0% in the 3rd quarter. Sandy Spring Bank now owns 6,200 shares of the company’s stock valued at $27,000 after acquiring an additional 4,200 shares in the last quarter. Executive Wealth Management LLC grew its holdings in shares of Aurora Cannabis by 102.1% in the 2nd quarter. Executive Wealth Management LLC now owns 3,900 shares of the company’s stock valued at $30,000 after acquiring an additional 1,970 shares in the last quarter. Kistler Tiffany Companies LLC grew its holdings in shares of Aurora Cannabis by 77.9% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 4,075 shares of the company’s stock valued at $32,000 after acquiring an additional 1,785 shares in the last quarter. Finally, Usca Ria LLC bought a new position in shares of Aurora Cannabis in the 3rd quarter valued at about $33,000. Institutional investors own 9.05% of the company’s stock.
Several equities analysts have recently weighed in on the company. Pi Financial set a $7.00 price objective on Aurora Cannabis and gave the company a “buy” rating in a report on Tuesday, October 15th. Zacks Investment Research upgraded Aurora Cannabis from a “sell” rating to a “hold” rating in a report on Thursday, September 12th. Compass Point set a $8.00 price objective on Aurora Cannabis and gave the company a “hold” rating in a report on Thursday, September 12th. Stifel Nicolaus restated a “sell” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Aurora Cannabis in a report on Thursday, September 12th. Finally, Piper Jaffray Companies decreased their price objective on Aurora Cannabis from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday. One analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $7.27.
Aurora Cannabis (NYSE:ACB) last issued its earnings results on Thursday, November 14th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.04. Aurora Cannabis had a negative net margin of 124.57% and a negative return on equity of 2.97%. The business had revenue of $57.02 million during the quarter, compared to the consensus estimate of $72.82 million. On average, equities research analysts anticipate that Aurora Cannabis Inc will post -0.11 earnings per share for the current year.
Aurora Cannabis Profile
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Read More: How to invest using market indexes
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.